These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23937224)

  • 1. Metformin in lung cancer: rationale for a combination therapy.
    Morgillo F; Sasso FC; Della Corte CM; Festino L; Manzo A; Martinelli E; Troiani T; Capuano A; Ciardiello F
    Expert Opin Investig Drugs; 2013 Nov; 22(11):1401-9. PubMed ID: 23937224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
    Morgillo F; Sasso FC; Della Corte CM; Vitagliano D; D'Aiuto E; Troiani T; Martinelli E; De Vita F; Orditura M; De Palma R; Ciardiello F
    Clin Cancer Res; 2013 Jul; 19(13):3508-19. PubMed ID: 23695170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes.
    Tan BX; Yao WX; Ge J; Peng XC; Du XB; Zhang R; Yao B; Xie K; Li LH; Dong H; Gao F; Zhao F; Hou JM; Su JM; Liu JY
    Cancer; 2011 Nov; 117(22):5103-11. PubMed ID: 21523768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.
    Chen H; Yao W; Chu Q; Han R; Wang Y; Sun J; Wang D; Wang Y; Cao M; He Y
    Cancer Lett; 2015 Dec; 369(1):97-102. PubMed ID: 26341687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin use and survival from lung cancer: A population-based cohort study.
    Menamin ÚC; Cardwell CR; Hughes CM; Murray LM
    Lung Cancer; 2016 Apr; 94():35-9. PubMed ID: 26973204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial.
    Fasano M; Della Corte CM; Capuano A; Sasso FC; Papaccio F; Berrino L; Ciardiello F; Morgillo F
    Clin Lung Cancer; 2015 Jan; 16(1):57-9. PubMed ID: 25242667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fixed-Dose Combinations of Pioglitazone and Metformin for Lung Cancer Prevention.
    Seabloom DE; Galbraith AR; Haynes AM; Antonides JD; Wuertz BR; Miller WA; Miller KA; Steele VE; Miller MS; Clapper ML; O'Sullivan MG; Ondrey FG
    Cancer Prev Res (Phila); 2017 Feb; 10(2):116-123. PubMed ID: 28052934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin in breast cancer: time for action.
    Goodwin PJ; Ligibel JA; Stambolic V
    J Clin Oncol; 2009 Jul; 27(20):3271-3. PubMed ID: 19487373
    [No Abstract]   [Full Text] [Related]  

  • 9. Metformin for non-small cell lung cancer patients: Opportunities and pitfalls.
    Levy A; Doyen J
    Crit Rev Oncol Hematol; 2018 May; 125():41-47. PubMed ID: 29650275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there still a role for mitomycin-based combination chemotherapy in treating patients with nonsmall cell lung cancer? A single institution experience.
    Vitale FV; Malaponte E; Calì S; Antonelli G; Panebianco V; Blandino R; Ferraù F
    J Oncol Pharm Pract; 2013 Sep; 19(3):202-7. PubMed ID: 23034407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
    Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
    Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy.
    Barner JC
    Clin Ther; 2011 Sep; 33(9):1281-8. PubMed ID: 21840054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of targeted agents in adjuvant therapy for non-small cell lung cancer.
    Kelly K
    Clin Cancer Res; 2005 Jul; 11(13 Pt 2):5027s-5029s. PubMed ID: 16000608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
    Carter CA; Chen C; Brink C; Vincent P; Maxuitenko YY; Gilbert KS; Waud WR; Zhang X
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):183-95. PubMed ID: 16724239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy in the treatment of non-small cell lung cancer.
    Hainsworth JD
    Am Fam Physician; 1997 May; 55(6):2265-72. PubMed ID: 9149654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecularly targeted therapies in locally advanced non-small-cell lung cancer.
    Devarakonda S; Morgensztern D; Govindan R
    Clin Lung Cancer; 2013 Sep; 14(5):467-72. PubMed ID: 23684057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
    Maione P; Gridelli C; Troiani T; Ciardiello F
    Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
    Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
    Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in chemotherapy for lung cancer.
    Lilenbaum RC
    Curr Opin Pulm Med; 1996 Jul; 2(4):285-9. PubMed ID: 9363153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.